Zacks Investment Research
13 Oct 2026, 15:45 UTC · 1h ago
Mirum's Livmarli Meets Phase III Goal in Ultra-Rare Liver Diseases
Impact · against what's priced in
Mirum Pharmaceuticals (MIRM) sees a positive catalyst from its Phase III EXPAND study meeting its primary and secondary endpoints, supporting a label expansion for Livmarli into ultra-rare cholestatic liver diseases. While the positive data is material, the revenue realization is delayed until late 2027 or 2028 pending an sNDA submission in early 2027.
- MIRM+0.70
No priced-in read yet
- In context
The Phase III EXPAND study met its primary endpoint with a statistically significant improvement in itch scores (1.81-point vs 0.83-point for placebo) and a 69% reduction in serum bile acids, expanding the addressable market beyond Alagille syndrome.
Read from the article alone
Search tags
